Adna is a new blood test that will tell you if Zytiga and Xtandi will or will not treat castration resistant prostate cancer. Imagine knowing if Zytiga and or Xtandi will fail to help you, before you spend months of time and thousands of dollars trying these drugs out. The test, called AdnaTest Prostate Cancer Panel [...]
An inherited genetic change, HSD3B1 gene causes Androgen Deprivation Therapy (ADT) to be less effective for treating metastatic prostate cancer. Physician-researcher Nima Sharifi, M.D. published this finding in the October, 2016 The Lancet Oncology. While Androgen Deprivation Therapy is effective for many men with advanced stage prostate cancer, prostate tumors eventually become resistant to ADT because the tumors make their own androgens. “A simple blood [...]
E4 is a steroid that may become a treatment for advanced prostate cancer, both alone and fin combination with hormone therapy. Ellen Dutman, MSc, a clinical researcher, studied E4 as a treatment to lower testosterone. “An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side effects that occur with other [...]
Androgen deprivation therapy (ADT, or, “hormone therapy”) may be linked to increased risk of having dementia. Researchers, Nead, Sinha and Nguyen reviewed nine studies by other researchers. Seven of those studies reported an adjusted effect estimate for dementia risk. That means that a majority of today’s evidence based research says that ADT and dementia probably [...]
Yervoy (ipilimumab) alone doesn’t help treat advanced prostate cancer patients. Yervoy activates the immune system by going after the CTLA-4 protein receptor that slows immune-system activity. But prostate cancer responds to Yervoy by increasing two other immune checkpoint molecules, PD-L1 and VISTA. And both send a don’t-eat-me signal to immune cells. That reaction is why Yerboy, by [...]